Oncorena AB
Quotes
Share:
Subscribe:

Lars Grundemar, CEO Oncorena AB

Thu, Dec 23, 2021 07:30 CET

Medium resolution

Original resolution

Subscribe

Related Releases

Oncorena Initiates the Phase I-II Clinical Trial with Orellanine in Advanced Kidney Cancer Patients at Karolinska University Hospital in Sweden Tue, Feb 01, 2022 07:45 CET

Oncorena Receives Approval of First in Patient Trial with Orellanine as a Potential Breakthrough Therapy in Metastatic Renal Cancer Patients Mon, Mar 01, 2021 08:00 CET